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Abstract
Different human retroviruses, such as Human Immunodeficiency Virus (HIV) and Human T-cell Lymphotropic Virus
(HTLV), can cause neurologic infection. However, a definitive diagnosis may be hampered by several factors.
Quantification of the viral or proviral load in cerebrospinal fluid (CSF) may be helpful in the diagnosis of nervous
system disorders due to retroviral infection and may influence the treatment approach. The present work discusses
retrovirus infection and neurologic impairment, as well as the usefulness of the determination of the HIV and HTLV
proviral or viral load in cerebrospinal fluid in cases of neurologic disorder, in light of recent advances in this field.
This study also discusses the different molecular techniques for quantifying the proviral load (real-time quantitative
PCR, droplet digital PCR, and semi-nested real-time reverse transcription PCR) that are currently available.
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Introduction
The Retroviridae family comprises enveloped RNA viruses
that can infect several hosts. The viral particle presents the
enzymes reverse transcriptase and integrase. Thus, after the
reverse transcription, the proviral DNA can be integrated
into host cell genome [1]. In this context, molecular assays
can be used to determine the presence and quantity of
both viral RNA and proviral DNA in the infected host cell
[2–5]. Human retroviruses, such as Human Immuno-
deficiency Virus (HIV) and Human T-cell Lymphotropic
Virus (HTLV), can cause neurologic infection [6–12].
However, in these cases, a definitive diagnosis can be very
challenging and helpful for the early treatment. The diffi-
culty is associated with distinct factors, such as the wide
range of symptoms that can be observed in both types of
infection and the similarity of those symptoms with those
of other diseases. This problem occurs not only in devel-
oping countries, where there is a high prevalence of infec-
tious agents, but worldwide. The presence of coinfections
and the possibility of secondary nervous system damage
due to dual infection are other factors that can complicate
the diagnosis [11, 13–16]. The presence of virus in the
central nervous system (CNS) of individuals without
neurologic alterations also hampers a conclusive diagnosis.
Therefore, in cases of CNS impairment, such as HTLV-
1–associated myelopathy and HIV-associated dementia,
viral quantification in cerebrospinal fluid (CSF) may clarify
the diagnosis [8, 13, 17–22].
In the current study, we discuss the usefulness of
HIV and HTLV-1 quantification in CSF among patients
with neurologic disorders due to retrovirus infection, on
the basis of the recent knowledge achieved in this field.
Review
Retrovirus infections and neurologic impairment
HTLV-1 can successfully infect the central nervous system
(CNS). Although the great majority of HTLV-1 infected
individuals remain asymptomatic throughout their life-
time, about 5 % may present a chronic, incapacitating
neurologic disorder [10, 23, 24]. This disorder, called
HTLV-1–associated myelopathy/tropical spastic parapar-
esis (HAM/TSP), is characterized predominantly by spinal
cord damage associated with HTLV-1 infection [10, 25].
Regarding HIV infection, severe neurocognitive condi-
tions, usually resulting in death, have been detected in
HIV-infected individuals since the beginning of the HIV
epidemic [6, 26]. This alteration was observed in persons
with advanced HIV-1 infection and was called HIV-
Associated Dementia (HAD) [27]. A few years later,
milder forms of neurocognitive impairment in HIV-1-
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infected persons were reported, occurring even before the
onset of advanced systemic disease [28]. After the introduc-
tion of combination antiretroviral therapy (cART), the
incidence of HAD decreased dramatically [29]. However,
milder forms of HIV-associated neurologic disorders be-
came highly prevalent. Thus, a new denomination was sug-
gested: HIV-associated neurocognitive disorders (HAND)
[7, 27]. According to this new terminology, HAND can be
further classified into asymptomatic neurocognitive impair-
ment (ANI), mild neurocognitive disorder (MND), and
HIV-associated dementia (HAD). HAND is estimated to
affect up to 50 % of HIV-infected individuals [7, 27]. It is
important to note that the prevalence of HAD decreased
in the cART era, but for mild to moderate HAND forms.
In fact, the prevalence of HAND in HIV-infected patients
without AIDS increased from 29 to 36 % after the imple-
mentation of combined antiretroviral therapy. There was
no significant difference in the prevalence of HAND
among AIDS patients [9].
HTLV proviral load in CSF
According to WHO guidelines for HAM/TSP diagnosis, a
patient can be classified under definitive HAM/TSP in the
presence of chronic progressive spastic paraparesis associ-
ated with antibodies detection in both blood and CSF. Some
individuals, however, do not present antibodies in CSF or do
not present the classical symptoms of disease, despite the
presence of antibodies in both compartments. Such individ-
uals are classified under probable HAM/TSP [30]. More-
over, in cases of recent infection and of passive transfer of
antibodies (as can occur in vertical transmission), antibodies
detection is not recommended due to false-positive or false-
negative results [31]. It is important to highlight that anti-
bodies can be passively transferred through the blood-CSF
barrier even in asymptomatic individuals [17].
The detection of HTLV-1 antibodies is done by screen-
ing (ELISA) and confirmatory tests (Western blot). Some
patients can present indeterminate or discordant Western
blot results [32, 33]. The same can occur in HIV diagnosis
[34]. In this context, tests that are able to detect and quan-
tify viral genome can be very useful. The HTLV-1 proviral
load (PVL) in blood is higher in HAM/TSP patients than
in asymptomatic carriers. However, previous studies have
failed to determine a reliable cutoff value for an accurate
HAM/TSP diagnosis [35, 36].
Regarding the PVL in CSF, patients with HAM/TSP were
found to present a higher PVL compared with asymptom-
atic HTLV-1–infected individuals [13, 17, 20, 21, 37].
Moreover, in HAM/TSP patients, the PVL CSF/PVL blood
ratio was always higher than 1 in HAM/TSP and lower
than 1 in AC [38] PVL in CSF inverse correlated with
intrathecal synthesis of HTLV-1 antibodies (HTLV-1 AI)
[12]. Another interesting point is that PVL in CSF com-
bined to intrathecal synthesis of HTLV-1 antibodies
analysis showed to be useful in discriminating between
HAM/TSP and multiple sclerosis (MS) [13]. This is ex-
tremely important because HTLV and MS present very
similar symptoms.
Therefore, the quantification of the PVL in CSF may
be a good marker for HAM/TSP diagnosis, mainly when
associated with other tests, such as HTLV-1 AI.
HIV viral and proviral load in CSF
The determination of the HIV viral load in blood is
widely used to assess the disease progression and the re-
sponse to antiretroviral therapy. As previously men-
tioned, HIV can infect the CNS, and HAND can be
observed even in patients with adequate control of viral
replication in plasma [7–9, 18, 22, 39]. The mechanism
that leads to the persistence of neurologic impairment in
patients with suppressed viral replication in the blood-
stream is poorly understood. Some authors consider
chronic inflammation, the presence of coinfections (such
as HCV), drug abuse, aging, and antiretroviral drug ef-
fects as factors that can contribute to the persistence of
HAND [15]. In this context, HIV compartmentalization
might play an important role in nervous system damage.
To understand HIV compartmentalization and its associ-
ation with HAND development, as well as acquired
drug resistance, some basic concepts of viral biology are
discussed.
HIV presents a high mutation rate, which can result in
the coexistence of viral quasispecies within a host. These
quasispecies evolve as a result of selection pressures, such
as those imposed by antiviral therapy, and can be restricted
to cells or tissues (compartmentalization) [40]. Previous
studies have described the HIV compartmentalization in
the CNS, which leads to selective replication of distinct
HIV quasispecies, resulting in resistance confined to the
CNS [19, 41]. It has also been pointed out that the mutated
virus may cause further viremia and may be related to re-
sistance to cART; Fig. 1 presents this mechanism. A recent
study showed that HIV-infected individuals presented
more resistant virus in CSF than in blood. This occurred in
both antiretroviral-naïve and treated patients, being more
frequent in the latter [42]. The administration of drugs that
are poorly distributed in the CNS is a factor that can con-
tribute to the development of drug-resistant virus in the
nervous system. Suboptimal adherence to the treatment
regimen may also lead to insufficient drug concentration in
CSF, which may also contribute to viral resistance [3, 8].
Thus, several studies have shown that HIV can escape in
CSF despite viral suppression in blood [3, 8, 18, 22, 43].
This evasion can contribute to discordant viral loads and
to a high viral load in CSF. A study of the HIV proviral
load in blood and CSF among HIV-seropositive individ-
uals with and without HAND found that the CSF proviral
load was greater in individuals with HAND than in those
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without HAND. Moreover, the PVL in seropositive pa-
tients was greater in CSF than in blood. The proviral
load was also observed to be greater in the blood and
CSF of subjects with more advanced systemic disease
and HAND [5]. Other studies have corroborated these
findings, showing a high viral load in CSF among pa-
tients with HAD [44].
These data highlight the importance of the quantification
of the proviral or viral load in CSF among HIV-infected
patients presenting neurologic disturbance and/or drug
resistance. In such cases, genotyping tests of CSF virus are
extremely important. In fact, some studies have reported
successful genotyping in CSF in cases in which it was not
possible to apply genotyping in blood [45].
Antiretroviral treatment and the proviral load
Previous studies have reported the effect of antiretroviral
treatment on the HIV proviral load. In particular, the
proviral load in CSF was shown to decrease after the im-
plementation of a therapeutic regimen with drugs with
improved CNS penetration [43].
Indeed, the drug concentration in the CNS seems to be
crucial for viral control in the nervous system. A recent
study tested two different therapeutic regimens with
distinct concentrations of darunavir. Only two patients
presented detectable viral genome in CSF, and those two
had the lower concentration of the drug in CSF despite
the prescribed dosage of orally administered drug, con-
firming that CSF assessment is an important issue [46].
Some drugs used as monotherapy, such as lopinavir/
ritonavir and zidovudine, had a significant effect on
decreasing CSF replication. In contrast, didanosine
and saquinavir were not able to control viral replica-
tion in CSF. Abacavir was also tested as an adjunctive
therapy in patients presenting HAD, with no effect in
CSF HIV RNA. In this context, a CNS penetration-
effectiveness (CPE) score was proposed. According to
the CPE, the antiretrovirals are scored from 1 to 4
(with 4 indicating the most neuro-effective drug). This
is determined based on the drug characteristics, phar-
macokinetic features, and pharmacodynamic properties.
The composite CPE can be calculated by summing single
drug scores to obtain the treatment score. Usually, a
higher CPE score is associated with a lower viral load in
CSF [47, 48].
Another important point associated with the successful
control of viral replication in CSF is related to viral resist-
ance. Thus, the therapeutic regimen should be modified
according to the results obtained by genotypic resistance
testing in CSF samples.
Regarding HTLV infection, the specific therapy for
HAM/TSP remains very disappointing, and symptomatic
treatment is still the most commonly used therapy [10].
There are few studies showing the impact of therapy on
the CSF PVL of HAM/TSP individuals. In one report,
after the corticosteroid therapy, the PVL in blood
decreased, but the PVL in CSF remained unchanged. The
patient presented an acute onset, a rapid progression, and
Fig. 1 Mechanism of HIV-acquired drug resistance with the central nervous system as reservoir. a Initial phase of HIV infection: HIV is replicating
in blood and access the CNS. b cART is initiated and controls the viremia. However, depending on the drug regimen, the drug access to the CNS
is poor, and HIV can efficiently replicate in this reservoir. As replication occurs, a mutated virus can be formed (compartmentalization). c Mutated
HIV enters the bloodstream. The mutated virus is able to replicate more efficiently in the cART poor environment (CNS) and could get into the
bloodstream. d The mutant drug-resistant virus replicates efficiently even with cART therapy. In such cases, the medication has to be changed.
The higher replication rate in the CNS is associated with the high proviral load in the CNS despite the proviral load in blood and is associated
with neurologic abnormalities in HIV-infected patients
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repeated exacerbation of neurologic symptoms, which is
not the classical presentation of HAM/TSP [20].
Molecular assays to determine the proviral and viral load
Currently, quantitative real-time polymerase chain reac-
tion (qPCR) and reverse transcription (RT)-qPCR are the
standard and most commonly used techniques to deter-
mine the proviral or viral load [37, 49, 50]. qPCR is known
to have high sensitivity, which is associated with the ability
to amplify the target gene, and high specificity, which is
related to primer annealing. In this context, there are two
main systems for the identification of the sign: the use of
fluorometric probes (such as the TaqMan system) and the
use of intercalating dyes (such as SYBR Green). The use of
a fluorometric probe increases the assay specificity once
the probe hybridizes to a complementary target sequence
in the target DNA, but not to nonspecific PCR products
or primer dimers, which may happen when intercalating
dyes are used [51, 52]. However, qPCR presents limita-
tions that can influence the accuracy of the test. The
dependence on a standard curve, for example, may result
in high inter-assay variability, mainly in compartments
with a low number of cells, such as CSF [53].
In this context, a novel technique, droplet digital PCR
(ddPCR), can also be used for viral or proviral load quanti-
fication. The advantage of this technique is that it does
not require a standard curve. In fact, ddPCR allows the
direct absolute quantification of a target gene, which can
positively influence the accuracy of the PVL quantifica-
tion. In a recent study, ddPCR presented low intra- and
inter-assay variability in the determination of the HTLV-1
PVL in CSF of infected patients. The same study con-
cluded that, regarding the HTLV-1 proviral load in periph-
eral blood mononuclear cells (PBMCs), the inter-assay
variability of ddPCR was lower compared with qPCR [37].
It is important to note, however, that ddPCR presented
false-positive signals when it was used to detect the viral
load in HIV-infected individuals [54].
Regarding HIV infection, because some individuals
can present viral replication suppressed below the detec-
tion limit of the available diagnostic methods [39], some
authors have suggested the use of a semi-nested real-
time reverse transcription PCR assay to determine the
plasma viral load. In this technique, two successive PCR
reactions are done to increase the sensitivity of the test
and, consequently, reduce the limit of detection [55].
Thus, semi-nested RT-qPCR may be an interesting alter-
native in patients with a low viral load. Nevertheless, no
study has applied this technique in CSF.
Regardless of the chosen technique, prior validation
is essential, that is, before implementation in CSF rou-
tine analysis. Cross-validation by multiple laboratories
is indicated.
Conclusions
The determination of the viral or proviral load in CSF of
HTLV-1– and HIV-infected individuals with neurologic
disease may be a good marker for diagnosis, considering
the proximity of the lesion and the local infection. The
association of PVL measurement with other tests, such as
PVL in blood and intrathecal synthesis of specific anti-
bodies analysis in HTLV infection and HIV genotyping,
might bring an important contribution to clinicians. In
some cases, it can make the difference for a conclusive
diagnosis or even to therapeutic approach. However, prior
validation of molecular assays before implementation in
laboratorial routine is essential, mainly regarding the CSF
examination. Many laboratories use the same method-
ology applied in blood, forgetting that CSF is a body fluid
with different constituents that may interfere in laboratory
tests. Even greater emphasis should be given to HTLV,
which, being a neglected disease, does not have approved
commercial kits for use in CSF testing; thus, “in-house”
tests are mandatorily used. In this case, the international
standardization of tests would be beneficial for the acqui-
sition of reliable and comparable results that would make
possible a better clinical interpretation of the laboratory
findings of patients.
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